He is a cancer researcher with the objective to create new therapies, one of which is ST-36 (co-discoverer), to promote regression and eradication of brain cancer. Dr. Angelastro’s research endeavors received federal funding from the NIH as principle investigator along with Dr. Lloyd A. Greene as co-investigator. He is part of the UC Davis core graduate teaching in pharmacology/toxicology, and professional veterinary medicine education in receptor signaling and pharmacodynamics. Dr. Angelastro has authored 35 publications and 4 book chapters, and currently has 2 patents granted and 2 patents pending.